Thank you, healthcare workers, for all you do. Your determination to help others is truly inspiring. Please stay safe.
Med-IQ
Attacking the Mechanisms of Moderate-to-Severe Atopic Dermatitis With Targeted Therapy

Attacking the Mechanisms of Moderate-to-Severe Atopic Dermatitis With Targeted Therapy

Med-IQ Select
Online Course | Specialties: Allergy and Immunology, Dermatology
Released: 10/8/2020
|
Expires: 10/7/2021
|
Max Credits: 1.0
Jump to Education

Faculty
Peck Ong, MD
Associate Professor of Clinical Pediatrics
Division of Clinical Immunology and Allergy
Children’s Hospital Los Angeles
Keck School of Medicine of USC
Los Angeles, CA

Jonathan I. Silverberg, MD, PhD, MPH
Associate Professor
Director of Clinical Research
Director of Patch Testing
Department of Dermatology
George Washington University School of Medicine and Health Sciences
Washington, DC
 
Activity Planners
Erin Mooney, MS
Clinical Content Manager
Med-IQ
Baltimore, MD

Lisa R. Rinehart, MS, ELS
Director, Editorial Services
Med-IQ
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Med-IQ
Baltimore, MD

Amy Sison
Director of CME
Med-IQ
Baltimore, MD

Writer
Katherine Kahn
Holyoke, MA
  
Learning Objectives
Upon completion, participants should be able to:

  • Use validated disease severity and quality of life assessment measures to identify patients with moderate-to-severe AD who may benefit from targeted biologic therapy
  • Define the role of inflammatory cytokines in the pathophysiology of and as treatment targets in moderate-to-severe AD
  • Evaluate the impact of recent clinical data for novel, targeted biologics on personalized treatment decisions for moderate-to-severe AD

Target Audience
This activity is intended for dermatology and allergy physicians, nurse practitioners, physician assistants, and fellows.
 
Statement of Need
Currently available validated, clinician-based and patient-reported atopic dermatitis (AD) assessment tools, used together, capture different pictures of this highly symptomatic disease and are important for more completely and accurately assessing disease severity and symptom burden. It has also been demonstrated that there can be discordance between clinician- and patient-reported control of AD symptoms, especially for patients with darker skin.

For appropriate patients with moderate-to-severe AD, numerous topical and systemic targeted agents have been approved by the FDA or are in late-stage development that suppress cytokine pathways central to AD pathogenesis.

Although several cytokine signaling pathways play a role in acute and chronic lesion formation, the Th2 cytokines IL-4 and IL-13 are key players in AD chronicity, and agents targeting these signaling pathways have proven to be the most efficacious as well as safe in clinical trials. The integration of FDA-approved targeted agents, or those likely to receive approval in the future, should be considered for patients with moderate-to-severe disease in a stepwise fashion, only after basic management strategies and topical treatment have been maximized and adherence to and failure of therapy have been confirmed.

Providership Statement
Provided by Med-IQ. 
 
Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CLAIMING MOC POINTS: If you intend to claim MOC points for your participation, you will need to provide your unique, six-digit ABIM ID Number. Please note, your name, ABIM ID number, birthdate, and completion status will be shared with ABIM through the ACCME PARS system. Your points will be automatically submitted to the ABIM on your behalf; please allow 4 weeks for your points to display on the ABIM website.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
This is a 1.0-credit CME activity. To receive credit, read the introductory CME material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: October 8, 2020
Expiration Date: October 7, 2021
Estimated Time to Complete This Activity: 1 hour

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Peck Ong, MD
Consulting fees/advisory boards: AbbVie Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc.
Contracted research: Incyte Corporation, Pfizer, Inc., Regeneron Pharmaceuticals, Inc.

Jonathan I. Silverberg, MD, PhD, MPH
Consulting fees/advisory boards: AbbVie Inc., Asana, Arena Pharmaceuticals Inc., Bluefin, Boehringer Ingelheim Pharmaceuticals, Inc., Celgene Corporation, Dermavant, Dermira, Eli Lilly and Company, Galderma Laboratories, L.P., GlaxoSmithKline, Glenmark, Incyte Corporation, Kiniksa Pharmaceuticals, Ltd., LEO Pharma, Inc., Luna Pharma, Menlo Therapeutics, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Realm Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.
Fees received for promotional/non-CME activities: Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.
Contracted research: Galderma Laboratories, L.P., GlaxoSmithKline

The writer, peer reviewers, and activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
 
Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-policy.html.

Acknowledgment of Commercial Support
This activity is supported by educational grants from Regeneron Pharmaceuticals and Sanofi Genzyme.
 
Copyright
© 2020 Med-IQ, Inc.

Abstract

Here are some key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available by clicking the "Continue" button below.

Welcome to this Med-IQ Select on the use of targeted biologics for the management of moderate-to-severe AD. Med-IQ Select is a unique online educational offering that allows you to pick and choose the content you would like to view—in any order and at your convenience. Key clinical takeaways from this activity include:

  • The validated clinician-based AD severity assessment tools EASI, SCORAD, and IGA differ but evaluate key symptoms of erythema, papulation, excoriation, and lichenification
  • Patient-reported outcome tools, such as POEM, PO-SCORAD, ADCT, Pruritus NRS, and DIQL, are critical and necessary components of assessing AD severity in patients; it has been demonstrated that there is discordance between clinician- and patient-reported control of AD
  • Numerous cytokine signaling pathways play a role in acute and chronic lesion formation in patients with AD, but IL-4 and IL-13, which are Th2 cytokines, are central to AD pathogenesis, and their signaling cascades are key targets of agents demonstrated to be efficacious and safe in clinical trials
  • The integration of FDA-approved, systemic-targeted agents for moderate-to-severe AD should be considered for patients in a stepwise fashion, only after basic management strategies and topical treatments have been maximized and adherence to and failure of therapy have been confirmed

View reference list.

Click "Continue" to proceed through this activity and/or receive credit. To receive credit and a certificate, you must complete all of the modules in this activity.

By clicking "Continue," you confirm that you have reviewed the CME information.
Continue
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.